Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Free Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Regenxbio (RGNX) Gains from Sales and Divestitures (2019 - 2025)

Historic Gains from Sales and Divestitures for Regenxbio (RGNX) over the last 5 years, with Q3 2025 value amounting to $732000.0.

  • Regenxbio's Gains from Sales and Divestitures rose 8769.23% to $732000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was $732000.0, marking a year-over-year increase of 8769.23%. This contributed to the annual value of $395000.0 for FY2024, which is 11584.7% up from last year.
  • According to the latest figures from Q3 2025, Regenxbio's Gains from Sales and Divestitures is $732000.0, which was up 8769.23% from $598000.0 recorded in Q2 2025.
  • In the past 5 years, Regenxbio's Gains from Sales and Divestitures ranged from a high of $732000.0 in Q3 2025 and a low of $68.0 during Q4 2022
  • For the 4-year period, Regenxbio's Gains from Sales and Divestitures averaged around $277071.2, with its median value being $183000.0 (2023).
  • Per our database at Business Quant, Regenxbio's Gains from Sales and Divestitures soared by 26901764.71% in 2023 and then surged by 6703.91% in 2025.
  • Quarter analysis of 4 years shows Regenxbio's Gains from Sales and Divestitures stood at $68.0 in 2022, then soared by 269017.65% to $183000.0 in 2023, then skyrocketed by 115.85% to $395000.0 in 2024, then surged by 85.32% to $732000.0 in 2025.
  • Its Gains from Sales and Divestitures stands at $732000.0 for Q3 2025, versus $598000.0 for Q2 2025 and $546000.0 for Q1 2025.